Soluble IFN-.beta.2/IL-6 binding protein its preparation, and pharmaceutical compositions containing it
US5621077A · kind A · utility
69Cited by
7References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 27, 1994 |
| Grant date | Apr 15, 1997 |
| Priority date | — |
| Expiry date | Oct 27, 2014 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/834
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Human natural IFN-.beta.2/IL-6 receptor and its soluble extracellular fragment are provided in substantially purified form and are shown to stimulate and to enhance beneficial effects of IFN-.beta.2/IL-6, such as its antiproliferative activity. Polyclonal and monoclonal antibodies raised against the soluble fragment of the receptor are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.